Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Receivables (2018 - 2026)

Sunshine Biopharma filings provide 9 years of Change in Receivables readings, the most recent being -$41293.0 for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 104.06% to -$41293.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $116173.0, a 95.03% decrease, with the full-year FY2025 number at $116173.0, down 95.03% from a year prior.
  • Change in Receivables hit -$41293.0 in Q4 2025 for Sunshine Biopharma, down from $649850.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q2 2024 to a low of -$986986.0 in Q3 2024.
  • Median Change in Receivables over the past 5 years was $3899.0 (2021), compared with a mean of $198826.5.
  • Biggest five-year swings in Change in Receivables: soared 3166200.0% in 2023 and later tumbled 1658.68% in 2024.
  • Sunshine Biopharma's Change in Receivables stood at $6669.0 in 2021, then soared by 7881.14% to $532262.0 in 2022, then decreased by 10.63% to $475659.0 in 2023, then skyrocketed by 113.81% to $1.0 million in 2024, then plummeted by 104.06% to -$41293.0 in 2025.
  • The last three reported values for Change in Receivables were -$41293.0 (Q4 2025), $649850.0 (Q3 2025), and -$65711.0 (Q2 2025) per Business Quant data.